Oral treatment with a Brachystemma calycinum D don plant extract reduces disease symptoms and the development of cartilage lesions in experimental dog osteoarthritis: Inhibition of protease-activated receptor 2

Annals of the Rheumatic Diseases

Volumn 69, Issue 6, 2010, Pages 1179-1184

  Boileau, Christelle ^a   Martel Pelletier, Johanne ^a   Caron, Judith ^a   Paré, Frédéric ^a   Troncy, Eric ^b   Moreau, Maxim ^b   Pelletier, Jean Pierre ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYSTEMMA CALYCINUM D DON PLANT EXTRACT; COLLAGENASE 3; INDUCIBLE NITRIC OXIDE SYNTHASE; J AND L POWDER; PLACEBO; PLANT EXTRACT; PROTEINASE ACTIVATED RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CRUCIATE LIGAMENT; ARTICLE; CARTILAGE CELL; CHONDROPATHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INHIBITION; EXPERIMENTAL DOG; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; JOINT FUNCTION; JOINT INSTABILITY; KNEE OSTEOARTHRITIS; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM;

ADMINISTRATION, ORAL; ANIMALS; ARTHRITIS, EXPERIMENTAL; CARTILAGE, ARTICULAR; CARYOPHYLLACEAE; DOGS; DRUG EVALUATION, PRECLINICAL; GAIT; OSTEOARTHRITIS; PHYTOTHERAPY; PLANT EXTRACTS; RECEPTOR, PAR-2;

EID: 77953727873     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.110965     Document Type: Article

References (44)

1. Martel-Pelletier J, Lajeunesse D, Pelletier JP. Etiopathogenesis of osteoarthritis. In: Koopman WJ, Moreland LW, eds. Arthritis and allied conditions. A textbook of rheumatology. Baltimore: Lippincott, Williams & Wilkins, 2005:2199-226.
2. Martel-Pelletier J, Boileau C, Pelletier J-P, et al. Cartilage in normal and osteoarthritis conditions. In: Pap T, ed. Best practice and research clinical rheumatology. East Sussex, UK: Rapid Medical Media, 2008:351-84.
3. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthr Cartil 2007;15:981-1000.
4. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 2008;16:137-62.
5. Smith M, Ghosh P. Experimental models of osteoarthritis. In: Moskowitz R, Howell D, Altman R, Buckwalter J, Goldberg V, eds. Osteoarthritis. Philadelphia: WB Saunders, 2001:171-99.
6. Smith MM, Little CB. Experimental models of osteoarthritis. In: Moskowitz RW, Altman RD, Hochberg MC, Buckwalter J, Goldberg V, eds. Osteoarthritis diagnosis and medical/surgical management. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2007:107-25.
7. Brandt KD, Mazzuca SA. Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs. Arthritis Rheum 2005;52:3349-59.
8. Dougados M. Symptomatic slow-acting drugs for osteoarthritis: what are the facts? Joint Bone Spine 2006;73:606-9.
9. Raynauld JP, Martel-Pelletier J, Bias P, et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis 2009;68:938-47.
10. Wu CY, Zhou TY, Xiao PG. A compendium of new China herbal medicine. Shanghai: Shanghai Science and Technology Press, 1990:43.
11. Stuessy TF. Plant taxonomy: the systematic evaluation of comparative data. Chichester, West Sussex: Columbia University Press, 2009.
12. Cheng YX, Zhou J, Tan NH, et al. Isolation and characterization of Brachystemidines A-E, novel alkaloids from Brachystemma calycinum. J Nat Prod 2002;65:750-2.
13. Lu Q, Zhang L, He GR, et al. Two new alkaloids from Brachystemma calycinum and their inhibitory effects on lymphocyte proliferation. Chem Biodivers 2007;4:2948-52.
14. Boileau C, Martel-Pelletier J, Caron J, et al. Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13. Arthritis Res Ther 2009;11:R41.
15. Moreau M, Lussier B, Doucet M, et al. Efficacy of licofelone in dogs with clinical osteoarthritis. Vet Rec 2007;160:584-8. (Pubitemid 46733140)
16. Moreau M, Dupuis J, Bonneau NH, et al. Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Vet Rec 2003;152:323-9. (Pubitemid 36395750)
17. Moreau M, Dupuis J, Bonneau NH, et al. Clinical evaluation of a powder of quality elk velvet antler for the treatment of osteoarthrosis in dogs. Can Vet J 2004;45:133-9. (Pubitemid 38351155)
18. Gillette RL, Angle TC. Recent developments in canine locomotor analysis: a review. Vet J 2008;178:165-76.
19. Fernandes JC, Martel-Pelletier J, Otterness IG, et al. Effects of tenidap on canine experimental osteoarthritis. I. Morphologic and metalloprotease analysis. Arthritis Rheum 1995;38:1290-303.
20. Cook JL, Lafeber F, Kuroki K, et al. The OARSI histopathology initiative: recommendations for histological assessments of osteoarthritis in the dog. Osteoarthritis Cartilage 2010; In press.
21. Boileau C, Martel-Pelletier J, Brunet J, et al. Oral treatment with PD-0200347, an alpha2delta ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. Arthritis Rheum 2005;52:488-500.
22. Sakakibara Y, Miura T, Iwata H, et al. Effect of high-molecular-weight sodium hyaluronate on immobilized rabbit knee. Clin Orthop Relat Res 1994;282-92.
23. Pelletier JP, Lascau-Coman V, Jovanovic D, et al. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. J Rheumatol 1999;26:2002-14.
24. Pelletier JP, Jovanovic D, Fernandes JC, et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998;41:1275-86.
25. Pelletier JP, Jovanovic DV, Lascau-Coman V, et al. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum 2000;43:1290-9.
26. Boileau C, Martel-Pelletier J, Fahmi H, et al. The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. Arthritis Rheum 2007;56:2288-98.
27. Boileau C, Martel-Pelletier J, Jouzeau JY, et al. Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors. J Rheumatol 2002;29:1446-53.
28. Smith G Jr, Myers SL, Brandt KD, et al. Effect of intraarticular hyaluronan injection on vertical ground reaction force and progression of osteoarthritis after anterior cruciate ligament transection. J Rheumatol 2005;32:325-34.
29. Ratcliffe A, Azzo W, Glazer PA, et al. In vivo and in vitro effect of Naproxen on normal articular cartilage: suppressed metalloproteinase activities and proteoglycan turnover rates. Trans Orthop Res Soc 1991;16:199.
30. Palmoski MJ, Brandt KD. In vivo effect of aspirin on canine osteoarthritic cartilage. Arthritis Rheum 1983;26:994-1001. (Pubitemid 13039818)
31. Déry O, Corvera CU, Steinhoff M, et al. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 1998;274:C1429-52.
32. Macfarlane, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev 2001;53:245-82.
33. Hollenberg MD, Compton SJ. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 2002;54:203-17.
34. Al-Ani B, Saifeddine M, Kawabata A, et al. Proteinase-activated receptor 2 (PAR(2)): development of a ligand-binding assay correlating with activation of PAR(2) by PAR(1)-and PAR(2)-derived peptide ligands. J Pharmacol Exp Ther 1999;290:753-60.
35. Hollenberg MD. Proteinase-mediated signaling: proteinase-activated receptors (PARs) and much more. Life Sci 2003;74:237-46.
36. Kawabata A, Kuroda R, Minami T, et al. Increased vascular permeability by a specific agonist of protease-activated receptor-2 in rat hindpaw. Br J Pharmacol 1998;125:419-22.
37. Busso N, Frasnelli M, Feifel R, et al. Evaluation of protease-activated receptor 2 in murine models of arthritis. Arthritis Rheum 2007;56:101-7.
38. Xiang Y, Masuko-Hongo K, Sekine T, et al. Expression of proteinase-activated receptors (PAR)-2 in articular chondrocytes is modulated by IL-1beta, TNF-alpha and TGF-beta. Osteoarthr Cartil 2006;14:1163-73.
39. Boileau C, Amiable N, Martel-Pelletier J, et al. Activation of proteinase-activated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science study. Arthritis Res Ther 2007;9:R121.
40. Mulè F, BaffiMC, Capparelli A, et al. Involvement of nitric oxide and tachykinins in the effects induced by protease-activated receptors in rat colon longitudinal muscle. Br J Pharmacol 2003;139:598-604. (Pubitemid 36819629)
41. Naito Y, Uchiyama K, Kuroda M, et al. Role of pancreatic trypsin in chronic esophagitis induced by gastroduodenal reflux in rats. J Gastroenterol 2006;41:198-208.
42. Cicala C, Morello S, Vellecco V, et al. Basal nitric oxide modulates vascular effects of a peptide activating protease-activated receptor 2. Cardiovasc Res 2003;60:431-7.
43. Wanstall JC, Gambino A. Proteinase-activated receptor (PAR)-mediated vasorelaxation in pulmonary arteries from normotensive and hypoxic pulmonary hypertensive rats. Pulm Pharmacol Ther 2004;17:97-103.
44. Seeliger S, Derian CK, Vergnolle N, et al. Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo. FASEB J 2003;17:1871-85.